On 9/13/24, Eagle Pharmaceuticals Inc (NASDAQ: EGRX) stock enjoyed a major increase of 12.5%, closing at $4.31. Moreover, trading volume in this advance was exceptionally high at 204% of normal. Relative to the market the stock has been weak over the last nine months and has declined -1.8% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, EGRX is expected to continue to be a modest Value Builder.
Eagle Pharmaceuticals has a current Value Trend Rating of B (Positive). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Eagle Pharmaceuticals has a very high Appreciation Score of 98 but a slightly negative Power Rating of 32, leading to the Positive Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment